{"url_path":"/sec/olma/8-k/2026-06-23/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1750284/0001193125-26-279483-index.html","accession_number":"0001193125-26-279483","cik":"0001750284","ticker":"OLMA","issuer_name":"Olema Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1750284/0001193125-26-279483-index.html","primary_entity_key":"0001750284","primary_entity_name":"Olema Pharmaceuticals, Inc."},"word_count":343,"has_tables":true,"body_markdown":"## Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn June 17, 2026, Olema Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter. A more complete description of each matter can be found in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2026 (the “Proxy Statement”). Voting results are, when applicable, reported by rounding fractional share voting down to the nearest whole number.\n\n \n\nProposal 1—Election of Directors\n\n \n\nFinal Voting Results\n\n \n\nNominees\n\n \n\nFor\n\n \n\nWithheld\n\n \n\nBroker Non-Votes\n\nSean Bohen, M.D., Ph.D.\n\n \n\n67,474,365\n\n \n\n1,165,382\n\n \n\n7,496,139\n\nScott Garland\n\n \n\n66,184,382\n\n \n\n2,455,365\n\n \n\n7,496,139\n\nYi Larson\n\n \n\n50,371,668\n\n \n\n18,268,079\n\n \n\n7,496,139\n\nAndrew Rappaport\n\n \n\n67,276,575\n\n \n\n1,363,172\n\n \n\n7,496,139\n\n \n\nThe Company's stockholders elected each of the four nominees as Class III directors to hold office until the Company’s 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified.\n\n \n\nProposal 2—Advisory Vote on Executive Compensation\n\n \n\nFinal Voting Results\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non-Votes\n\n67,969,902\n\n \n\n653,979\n\n \n\n15,867\n\n \n\n7,496,139\n\n \n\nThe Company’s stockholders approved, on an advisory basis, the compensation awarded to the Company’s named executive officers, as disclosed in the Proxy Statement.\n\n \n\nProposal 3—Ratification of Selection of Independent Registered Public Accounting Firm\n\n \n\nFinal Voting Results\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n75,811,449\n\n \n\n271,918\n\n \n\n52,520\n\n \n\nThe Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.\n\n \n\nNo other matters were submitted for stockholder action.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nOLEMA PHARMACEUTICALS, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 23, 2026\n\nBy:\n\n/s/ Sean Bohen, M.D., Ph.D.\n\n \n\n \n\n \n\nSean Bohen, M.D., Ph.D.\nPresident and Chief Financial Officer"}